Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CMRX | Common Stock, par value $0.001 | Sale | -$37.4M | -6.5M | -65% | $5.75* | 3.5M | Sep 14, 2021 | Direct |
Cantex Pharmaceuticals, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.